MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2022 International Congress

    Natural progression of patients with Parkinson disease on less pulsatile levodopa therapy

    M. Lin, R. Laureno, A. Lenka (Washington, USA)

    Objective: To evaluate the natural progression of Parkinson disease (PD) in patients on less pulsatile levodopa therapy (LPT). Background: Previously we have shown that patients…
  • 2022 International Congress

    Comparing duodenal levodopa infusion based on length of treatment in advanced Parkinson’s.

    J. Alonso Maroto, E. Casas Peña, I. Muro García, M. Domínguez Gallego, E. Valiente Gordillo, L. López Manzanares, JA. Vivancos Mora (Madrid, Spain)

    Objective: In this study we seek to compare characteristics and complications of patients suffering from advanced Parkinson's treated with duodenal levodopa infusion. Background: Motor fluctuations…
  • 2022 International Congress

    Heart rate variability is affected by standing and medication intake in Parkinson’s disease

    F. Cucinotta, F. Morgante, I. Cociasu, E. Pereira, E. Makovac, L. Ricciardi (London, United Kingdom)

    Objective: To evaluate the effect of levodopa and orthostatism on heart rate variability (HRV) in a sample of consecutive subjects with Parkinson's disease (PD). Background:…
  • 2022 International Congress

    Globus pallidus as a neurosurgical target in the management of levodopa-induced dyskinesias

    A. Simonyan, V. Tyurnikov, V. Poleshuk, A. Simonyan, A. Gushcha (Moscow, Russian Federation)

    Objective: Parkinson's disease (PD) is a neurodegenerative disorder characterized by the development of motor symptoms, as well as some non-motor changes. Symptomatic treatment of PD…
  • 2022 International Congress

    Subgroup analyses by Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) of patients treated with levodopa inhalation powder 84mg or placebo to treat OFF symptoms in patients with Parkinson’s disease (PD)

    D. Grosset, P. Zhao, R. Marini, R. Cohen, B. Blank (Glasgow, United Kingdom)

    Objective: An analysis of the proportion of patients who turned ON after levodopa inhalation powder (CVT-301) 84mg treatment vs placebo, compared across subgroups of patients…
  • 2022 International Congress

    The benefit of exclusive nocturnal administration of a levodopa-carbidopa intestinal infusion for severe refractory sleep behavior disorder in Parkinson’s disease

    M. Rivera Sánchez, A. Sánchez Rodríguez, M. Sierra, I. González-Aramburu, MV. Sánchez Peláez, M. Martínez, J. Infante (Santander, Spain)

    Objective: Treatment by continuous diurnal intestinal infusion of levodopa is effective in improving sleep quality in Parkinson's disease (PD), but its use exclusively at night…
  • 2022 International Congress

    Levodopa Carbidopa Intestinal Gel in Patients with Deep Brain Stimulation in Parkinson’s disease- First case series from Middle-East Region

    S. Mittal, A. Aldakheel, W. Mohammed, T. Alkhairallah, B. Klassen, M. Thomas, T. Maiti, S. Wasti (Abu Dhabi, United Arab Emirates)

    Objective: The objective is to report unique and challenging cases, who had successful control of Parkinson’s disease (PD) symptoms with combination therapy of Deep Brain…
  • MDS Virtual Congress 2021

    Effect of the GlyT1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset

    I. Frouni, SG. Nuara, D. Bédard, A. Hamadjida, JC. Gourdon, P. Huot (Montreal, Canada)

    Objective: To determine the effect of glycine transporter 1 (GlyT1) inhibition with ALX-5407 on dyskinesia, psychosis-like behaviours (PLBs) and parkinsonism severity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned…
  • MDS Virtual Congress 2021

    Locus coeruleus degeneration associated with less levodopa responsiveness in Parkinson’s Disease

    C. Zhou, B. Zhang, M. Zhang (Hangzhou, China)

    Objective: We aimed to explore the relationship between LC degeneration and levodopa responsiveness in Parkinson’s Disease (PD) patients in vivo. Background: Widely divergent responsiveness of…
  • MDS Virtual Congress 2021

    LY-487,379 alleviates parkinsonism when administered as monotherapy in the MPTP-lesioned marmoset

    I. Frouni, C. Kwan, S. Nuara, S. Belliveau, A. Hamadjida, W. Kang, D. Bédard, J. Gourdon, P. Huot (Montreal, Canada)

    Objective: To determine the effect of selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulation as monotherapy on parkinsonism, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset. Background: We…
  • « Previous Page
  • 1
  • …
  • 28
  • 29
  • 30
  • 31
  • 32
  • …
  • 70
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley